Adeno-associated virus (AAV) vectors are currently the leading candidates for virus-based gene therapies because of their broad tissue tropism, non-pathogenic nature and low immunogenicity 1 . They have been successfully used in clinical trials to treat hereditary diseases such as haemophilia B (ref. 2), and have been approved for treatment of lipoprotein lipase deficiency in Europe 3 . Considerable efforts have been made to engineer AAV variants with novel and biomedically valuable cell tropisms to allow efficacious systemic administration 1,4 , yet basic aspects of AAV cellular entry are still poorly understood. In particular, the protein receptor(s) required for AAV entry after cell attachment remains unknown. Here we use an unbiased genetic screen to identify proteins essential for AAV serotype 2 (AAV2) infection in a haploid human cell line. The most significantly enriched gene of the screen encodes a previously uncharacterized type I transmembrane protein, KIAA0319L (denoted hereafter as AAV receptor (AAVR)). We characterize AAVR as a protein capable of rapid endocytosis from the plasma membrane and trafficking to the trans-Golgi network. We show that AAVR directly binds to AAV2 particles, and that anti-AAVR antibodies efficiently block AAV2 infection. Moreover, genetic ablation of AAVR renders a wide range of mammalian cell types highly resistant to AAV2 infection. Notably, AAVR serves as a critical host factor for all tested AAV serotypes. The importance of AAVR for in vivo gene delivery is further highlighted by the robust resistance of Aavr −/− (also known as Au040320 −/− and Kiaa0319l −/− ) mice to AAV infection. Collectively, our data indicate that AAVR is a universal receptor involved in AAV infection.
which were implicated in heparan sulfate proteoglycan biosynthesis (depicted in blue). AAV2 hijacks endosomal pathways to travel from the cell surface to the nucleus, and several endosomal trafficking genes (depicted in green) were prominently identified in the screen, specifically those encoding members of the retromer (VPS29, VPS35) and Golgi-associated retrograde protein complexes (VPS51, VPS52, VPS53, VPS54). These proteins are involved in retrograde transport from the endosomes to the Golgi 9,10 , but have not been specifically associated with AAV2 infection before now. The most significantly enriched gene of the screen was KIAA0319L (denoted hereafter as AAVR), with 570 independent mutations identified. This gene encodes a poorly characterized transmembrane protein. Little is known about the cellular function of AAVR, but it has been linked to dyslexia, with a potential role in neuronal migration 11 .
To validate the role of AAVR in AAV2 infection, we used CRISPR-Cas9 genome engineering to generate isogenic AAVR-knockout (AAVR KO ) cell lines in a panel of cell types representing various human and mouse tissues (Extended Data Table 1 ). In all eight cell types, AAVR knockout rendered cells highly resistant to AAV2 infection (20,000 viral genomes (vg) per cell) ( Fig. 1b) . At a multiplicity of infection as high as 100,000 vg per cell, AAVR KO cells still remained poorly susceptible to infection by an AAV2-luciferase vector (Extended Data Fig. 3a ). This also held true for wild-type AAV2 infection, where AAV2 replication was negligible in AAVR KO cells (Extended Data Fig. 3b ). Notably, MET and FGFR1 knockouts demonstrated no resistance to infection in multiple cell types (Extended Data Fig. 3e ). Genetic complementation of AAVR in AAVR KO cells (Extended Data Fig. 3c ) restored susceptibility to AAV2 in all cell types assessed, confirming that the resistance phenotype observed in AAVR KO cells was caused by loss of AAVR expression (Extended Data Fig. 3d ). To examine further if AAVR expression can limit AAV2 infection, we overexpressed AAVR in four cell lines previously identified as poorly permissive to AAV2 (refs 12, 13) . We observed an increase in susceptibility to AAV2 in all AAVR-overexpressing cell lines compared to wild-type cells, emphasizing the important role of AAVR in AAV2 infection (Fig. 1c ).
AAVR is a predicted type I transmembrane protein with five immunoglobulin-like (Ig-like) domains in its ectodomain, referred to as polycystic kidney disease (PKD) domains 14 . Ig-like domains mediate cell-cell adhesion and are present in various well-characterized virus receptors 15 , including those for poliovirus, measles virus and reovirus. On the basis of their similarity to other receptors and the heavy dependence of AAV2 infection on AAVR, we hypothesized that AAVR acts as an AAV2 receptor. We first determined whether AAVR PKD domains are responsible for mediating AAV2 infection by creating a series of AAVR deletion mutants and expressing each in AAVR KO cells ( Fig. 2a ). Simultaneous deletion of AAVR PKD domains 1 and 
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in other regions were tolerated ( Fig. 2b ). An AAVR minimal mutant (miniAAVR) consisting of PKD domains 1-3 in the ectodomain efficiently rescued AAV2 infection, highlighting the importance of the first three PKD domains for infection. Notably, soluble AAVR (recombinant protein comprising a fusion between maltose-binding protein (MBP) and AAVR PKD domains 1-5 expressed in Escherichia coli), but not MBP alone, bound directly to AAV2 particles ( Fig. 2c and Extended Data Fig. 4a ) with a dissociation constant (K d ) of ~150 nM (measured using surface plasmon resonance, see Extended Data Fig. 4b ). We next investigated whether AAV2 infection could be neutralized in the presence of soluble AAVR. Indeed, infection efficiency was inhibited in a concentration-dependent manner when soluble AAVR was included during infection ( Fig. 2d and Extended Data Fig. 4c ). Consistent with this inhibition assay, antibodies directed against AAVR were capable of potently blocking AAV2 infection by more than tenfold when incubated with cells before infection, in contrast to control IgG antibodies ( Fig. 2e ). This suggests that blocking viral access to AAVR on the cell surface substantially limits infection.
Characterization of the subcellular localization of AAVR revealed distinct perinuclear localization, demonstrating a strong association with the cis-medial Golgi marker (giantin), and complete co-localization with the trans-Golgi network (TGN) marker (TGN46) ( Fig. 3a) . Many TGN proteins are dynamically recycled from the plasma membrane through motifs in their carboxy terminal cytoplasmic tail (C-tail) that direct endocytosis and intracellular trafficking (reviewed in refs 16, 17).
To determine whether AAVR is such a recycling receptor, we specifically labelled the cell surface pool of AAVR by incubating live AAVR-complement cells with anti-AAVR antibodies under cold conditions. Cells were warmed to initiate endocytosis and fixed at defined time points. Labelled AAVR gradually moved from the surface into the cell, and concentrated in a perinuclear location associated with the Golgi marker ( Fig. 3b ). This rapid endocytosis may explain why we did not observe AAVR at the cell surface in steady state ( Fig. 3a) . As a control, AAVR KO cells were labelled similarly to AAVR-expressing cells, but no AAVR was detected on these cells (Extended Data Fig. 5a ). Interestingly, the intracellular trafficking route of AAVR mapped here is remarkably similar to that of AAV particles, trafficking from the plasma membrane to the Golgi 18 . To determine whether AAVR endocytosis contributes to mediation of AAV2 infection, we removed the C-tail, which encodes endocytic motifs of AAVR. C-tail deletion (ΔC-tail) led to increased cell surface expression of AAVR ( Fig. 3c and Extended Data Fig. 5b ) and prevented endocytosis (Extended Data Fig. 5c ). Importantly, the ΔC-tail was incapable of mediating AAV2 infection upon complementation in AAVR KO cells ( Fig. 3d ), suggesting that AAVR endocytosis is required for AAV2 infection. We further investigated whether AAVR requires intracellular trafficking to the TGN to mediate infection by replacing the C-tail of miniAAVR with those of cellular receptors with well-characterized endocytic motifs (Extended Data Fig. 6a ). These included the cation-independent mannose 6-phosphate receptor (Ci-MPR), the prototypical receptor that mediates trafficking from the plasma membrane to the TGN 19 . We also included the low density lipoprotein receptor (LDLR) 20 and poliovirus receptor (PVR) 21 , both of which endocytose and traffic between the plasma membrane and endosomes but are not reported to travel to Fig. 6b ). Remarkably, all fusion constructs rescued AAV2 infection, albeit to different degrees (Extended Data Fig. 6c ). Compared to the restored infection in miniAAVR-expressing cells, the LDLR and PVR fusion constructs yielded twofold and fourfold reduced infectivity, respectively. Conversely, routeing AAVR to the TGN using Ci-MPR endocytosis signals resulted in infection rates similar to miniAAVR-expressing cells. Thus, trafficking to the TGN appears to increase AAV infection efficiency, but varying rates of endocytosis between the constructs may also contribute to infectivity differences. Nonetheless, all fusion constructs rescued infectivity to an extent, even those that are not reported to traffic to the TGN, indicating that trafficking to the TGN may not be a strict requirement. Collectively, these data suggest a model where AAVR interacts with AAV at the cell surface and facilitates trafficking to the TGN, but do not exclude the possibility that the interaction is initiated in early/late endosomes and/or the TGN.
To test whether other naturally occurring AAV serotypes are also dependent on AAVR, we infected AAVR KO cells with a panel of AAV serotypes including AAV1, 2, 3B, 5, 6, 8 and 9 (expressing green fluorescent protein (GFP) or RFP). We also infected cells with a recombinant adenovirus 5 vector expressing RFP (Ad5-RFP). AAVR KO cells displayed a robust resistance to all AAV serotypes ( Fig. 4a ), irrespective of the different glycan attachment factors used by each serotype. AAV susceptibility was also restored in AAVR-complemented cells, as previously observed with AAV2. Moreover, there was no significant difference in Ad5-RFP infection among the three cell lines tested. The role of AAVR in infection for the tested viruses is therefore specific to AAV and is ubiquitously required for a variety of human-and simianderived AAV serotypes.
Finally, we tested the contribution of AAVR to in vivo gene delivery. We generated Aavr-knockout mice (Aavr −/− ) using transcription activator-like effector nuclease (TALEN)-mediated gene targeting. Aavr −/− mice did not display any apparent developmental or physical phenotype. Wild-type (Aavr +/+ ), heterozygous (Aavr +/− ) and Aavr −/− FVB mice (genotypes depicted in Extended Data Fig. 7a ) were injected intraperitoneally with AAV9-luciferase, chosen because of its high transduction efficiency in vivo compared to AAV2 (ref. 22 ). Bioluminescence (a measure of luciferase expression) was strongest in the lower abdomen of Aavr +/+ mice, intensifying over 14 days (Fig. 4b, c and Extended Data Fig. 7b ). Aavr heterozygosity did not significantly reduce AAV9 infection in vivo; however, Aavr −/− mice displayed a pronounced reduction in bioluminescence, comparable to background levels obtained in uninfected wild-type mice ( Fig. 4d and Extended Data Fig. 7c ).
Overall, this study identifies AAVR as a key host receptor for AAV infection in vitro and in vivo, using an unbiased and comprehensive genetic screening approach. AAV vector usage for gene therapy is rapidly growing, and recent advances in genome editing 23 and vectored immunoprophylaxis 24 are expected to further expand its utility. Exploiting AAVR as a tool to improve AAV-based applications may enhance its efficacy in basic research and clinical settings. An understanding of AAVR tissue distribution will be important in determining the contribution of AAVR to AAV tropism, although additional factors 25 including glycan usage, AAV nuclear import and other genes identified in our screen could also influence tropism. Lastly, AAV vectors are commonly used in experimental mouse models; hence expression of AAVR under specific promoters (for example, for cells in the substantia nigra) in an Aavr −/− background may aid in developing better mouse models for human diseases such as those for neurological disorders.
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MethOdS Cell lines and viruses. All cells were grown in media supplemented with 10% fetal calf serum (FCS) (Sigma), 100 IU ml −1 penicillin/streptomycin (Sigma) and 2 mM l-glutamine (Sigma), and grown in a humidified incubator at 37 °C with 5% CO 2 . HAP1 (ref. 8) cells and K562 cells (American Type Culture Collection (ATCC)) were cultured in complete IMDM media. HT29, U2OS (both obtained from ATCC), Caco-2, A549 (both gifts from L. Popov), HEK-293T (from Thermo Scientific), H1-HeLa (from ATCC), HuH7 (a gift from P. Sarnow), mouse embryonic fibroblasts (a gift from K. Storek) and NIH3T3 (a gift from W. Kaiser) cells were all cultured in complete DMEM media. Raji cells (expressing DC-SIGN) (a gift from E. Harris) were cultured in complete RPMI media. The cell lines have not been authenticated or tested for mycoplasma contamination. All isogenic knockout clones were grown in the same media as parent cell lines. HAP1 cells were used for haploid genetic screens (see later). Purified, titred stocks of AAV serotypes 1, 2, 3B, 5, 6, 8 and 9 were purchased from University of North Carolina Chapel Hill Gene Therapy Center Vector Core. These were all self-complementary AAV vectors encoding a reporter fluorescent gene (either GFP or RFP). Purified titred stocks of AAV9-luciferase were also purchased from this core facility to perform mouse experiments. Adenovirus type 5 vector carrying mCherry (Ad5-RFP) was constructed by cloning mCherry cDNA in the pAd/CMV/V5-DEST gateway vector (Invitrogen) according to the manufacturer's protocol. Antibodies. The following antibodies were used in this study: mouse polyclonal anti-KIAA0319L (ab105385) and rabbit polyclonal anti-giantin (ab24586) (Abcam); rabbit polyclonal anti-TGN46 antibody (NBP1-49643) (Novus Biologicals); mouse monoclonal anti-GAPDH (GT239) (Genetex); rabbit polyclonal anti-FGFR1 (D8E4) and rabbit IgG2a isotype control (Cell Signaling Technology); mouse monoclonal phycoerythrin-conjugated anti-MET antibody (95106) and phycoerythrin-conjugated mouse IgG1 isotype control (R&D Systems, Inc). A high-affinity F-actin, fluorescently labelled probe (Alexa Fluor-660 phalloidin) was used to visualize the cell interior and periphery (Life Technologies). Virus infections. Cells were seeded at 10,000 cells per well (96-well plate) overnight. They were then infected with AAV at a MOI of 20,000 vg per cell (unless otherwise specified) in complete DMEM. Virus infectivity was determined 24 h after infection by measuring transgene expression (RFP, GFP or luciferase) using flow cytometry or bioluminescence. In the case of wild-type AAV2 infection, HeLa wildtype or AAVR KO cells were seeded overnight, then infected with wild-type AAV2 (MOI: 1,000 vg per cell) in the presence of wild-type Ad5 (helper virus). RNA was collected using the Ambion Cell-to-C T kit (Thermo Scientific) 24 h after infection, and the generated cDNA was used to perform quantitative reverse-transcriptase PCR (RT-qPCR). mRNA levels of the AAV2-encoded rep68 gene were measured (as a means to detect viral replication) and normalized to 18S ribosomal RNA. Primers against rep68 cDNA included: 5′-CCAATTACTTGCTCCCCAAA-3′ and 5′-CGTTTACGCTCCGTGAGATT-3′. Primers against 18S rRNA included: 5′-AGAAACGGCTACCACATCCA-3′ and 5′-CACCAGACTTGCCCTCCA-3′. Ad5-RFP was used to infect cells to obtain 50-60% transduction (Fig. 4a ), and flow cytometry was used to measure RFP expression. All infections were performed in triplicate, and all data presented are representative of at least two independent experiments. Haploid genetic screen. The haploid genetic screen was performed similarly to the protocol described in ref. 8 with minor changes. Briefly, gene-trap virus was used to create a mutagenized HAP1 library. Of this mutagenized library, 100 million cells were infected with AAV2-RFP at a MOI 20,000 of vg per cell. After 48 h, infected cells were sorted by FACS, where RFP-negative cells (approximately 4% of the population) were sorted and grown over a period of 4 days. The resulting sorted cells were then infected again with AAV2 as before, and re-sorted to enrich the RFP-negative (AAV-resistant) population. Thirty-million cells of the resistant population were used for genomic DNA isolation. We performed sequence analysis of gene-trap insertion sites, and the significance of enrichment for each gene in the screen was calculated by comparing how often that gene was mutated and how often the gene carried an insertion in the control data set (owing to random integration). For each gene, a P value was calculated using the one-sided Fisher exact test in R. The P values were corrected for multiple testing according to the Benjamini and Hochberg method (using the R statistical package), to control for false discovery rate 26 . In the case of KIAA0319L, the P value was lower than the software could report. The numerical value was thus set to 1 × 10 −307 (smallest non-zero normalized floating-point number R could report). Generation of isogenic knockout cell lines. CRISPR-Cas9 gene editing technology was used to generate isogenic knockout alleles by targeting exonic sequences shared among all protein-coding transcripts of the respective genes as described in ref. 27 . The targeted sequences are depicted in Extended Data Table 1 , along with the respective mutations. CRISPR sequence targeting oligonucleotides were designed using the Zhang lab CRISPR design tool (http://crispr.mit.edu).
Oligonucleotides corresponding to the guide RNA (gRNA) sequences in Extended Data Table 1 were synthesized (Integrated DNA Technologies). gRNA oligonucleotides were directly cloned into Cas9-expressing plasmids pX330 or pX458 (generated by the Zhang lab; obtained from http://www.addgene.org; plasmid 42230 or 48138). Respective cells were transiently transfected with gRNA-encoding plasmids (and GFP-expressing pcDNA vector with gRNA-pX330 plasmids) using Fugene (Promega). After 48 h, GFP-expressing cells were subcloned using the BD InFlux Cell Sorter at the Stanford Shared FACS facility. They were then expanded over 2 weeks and screened genotypically for the mutated allele by extracting genomic DNA from subclones (using the quick DNA universal 96-kit; Zymo Research), amplifying a 500-700 base-pair (bp) region that encompassed the gRNA-targeted site, and sequencing (ElimBio) the resulting PCR product to identify subclones with knockout mutations. The B3GALT6 isogenic knockout clone was generated using TALENs directed against the nucleotide sequence 5′-TGGCCATGCTGGCCTGGCTG-3′, and the reverse complement sequence of 5′-GAGTTCGTGCTCAAGGCGGA-3′ in the only exon of B3GALT6 (transcript ENST00000379198) as described previously 28 . One day after transfection, cells were selected with blasticidin S (30 μg ml −1 , InvivoGen) for 24 h, then stained using anti-heparan sulfate antibody. Cells displaying low staining intensity were subcloned by FACS.
Construction of plasmids.
To generate the AAVR full-length construct and ΔC-tail, Gibson assembly reaction kit (New England Biolabs) was used to insert the gene of interest into a lentiviral-based vector, pLenti-CMV-Puro-DEST (w118-1) (plasmid 17452), digested with EcoRV to remove the DEST cassette (a gift from E. Campeau) 29 . AAVR and derived AAVR genes were amplified from a KIAA0319L cDNA clone (clone ID 3843301) (GE Dharmacon), but a single nucleotide polymorphism at position 447 was changed from a 'T' to a 'G' , allowing the sequence to align to the annotated human genome. The following primers were used to generate PCR products from the human KIAA0319L cDNA to be cloned directly into pLent-CMV-Puro-DEST. AAVR full-length: 5′-ATGTGTGGTGGAATTCTGCAGATACCATGGAGAAGAGGCTGGG-3′ and 5′-CG GC CG CC AC TG TG CT GG AT TT AC TT AT CG TC GT CA TC CT TG TA AT CCAGGATCTCCTCCCGC-3′; ΔC-tail: 5′-GACTCTAGTCCAGTGTGGTG-3′ and 5′-CGGCCGCCACTGTGCTGGATTTACTTATCGTCGTCATCCT TGTAATCTCCTTTTTGCCTCTTACAAC-3′. Note that reverse primer was designed to incorporate a C-terminal 1× Flag-tag sequence.
To generate the AAVR deletion constructs, two or three PCR products were generated using the AAVR construct (with Flag-tag) as a template. They were then assembled into the pLenti-CMV-Puro-DEST vector using the Gibson assembly reaction. Primers used to amplify the N-terminal fragments for the following constructs were: ΔMANEC: 5′-GACTCTAGTCCAGTGTGGTG-3′ and 5′-CTCA CTGGCATCTGTTGAC-3′; ΔPKD1-2: 5′-GACTCTAGTCCAGTGTGGTG-3′ and 5′-CAGTTCCTTTATAACTGGGTATGG-3′; ΔPKD2-3: 5′-GACT CTAGTCCAGTGTGGTG-3′ and 5′-CTTACGGGGCTCTGGC-3′; ΔPKD3-4: 5′-GACTCTAGTCCAGTGTGGTG-3′ and 5′-GTAATCCACAGCTTTG TTCAC-3′; ΔPKD4-5: 5′-GACTCTAGTCCAGTGTGGTG-3′ and 5′-CTTATTG TTTTCAGGTTGCACAAT-3′; miniAAVR: 5′-GACTCTAGTCCAGTG TGGTG-3′ and 5′-CTCACTGGCATCTGTTGAC-3′; middle fragment of min-iAAVR: 5′-GTCAACAGATGCCAGTGAGGTATCTGCTGGAGAGAGTGTC-3′ and 5′-CTTATTGTTTTCAGGTTGCACAAT-3′.
Primers used to amplify the C-terminal fragments for the following constructs were:
ΔMANEC: 5′-GTCAACAGATGCCAGTGAGACACACTCCTCCAAT TCCAT-3′ and 5′-ATCCAGAGGTTGATTGTCGAG-3′; ΔPKD1-2: 5′-CCATA CCCAGTTATAAAGGAACTGCCCCCTGTGGCCAACG-3′ and 5′-ATCCA GAGGTTGATTGTCGAG-3′; ΔPKD2-3: 5′-GCCAGAGCCCCGTAA GCCTCCTCAGGCAGATGC-3′ and 5′-ATCCAGAGGTTGATTGTCGAG-3′; ΔPKD3-4: 5′-GTGAACAAAGCTGTGGATTACCCACCTATAGCC AAGATAACTG-3′ and 5′-ATCCAGAGGTTGATTGTCGAG-3′; ΔPKD4-5: 5′-A TTGTGCAACCTGAAAACAATAAGAACCTGGTGGAGATCATCTTGGATA TC-3′ and 5′-ATCCAGAGGTTGATTGTCGAG-3′; miniAAVR: 5′-ATTGTGCAAC CTGAAAACAATAAGTGTGAGTGGAGCGTGTTATATG-3′ and 5′-ATCCAGA GGTTGATTGTCGAG-3′.
AAVR PKD domains 1-5 (residues 311-787) were expressed in E. coli using the pMAL expression system (New England Biolabs). A bacmid, created from a pFastBac dual vector containing the cDNA for the KIAA0319L ectodomain fused to a C-terminal influenza haemagglutinin (HA)-tag was a gift from M. van Oers, and obtained with the assistance of M. Waye 30 . cDNA coding for PKD domains 1-5 was cloned out of the pFastBacDual expression vector and inserted into the pMAL-c5X vector, using 5′-GTATCTGCTGGAGAGAGTGTCCAGATAACC-3′ and 5′-CAGGTTGTTTTTCCTGCAGGTCACCTGGGATCAGGTTTCAC-3′, then expressed in NEBexpress cells (New England Biolabs). This resulted in a fusion protein comprised of a mannose-binding protein (MBP) tag and AAVR Letter reSeArCH PKD domains 1-5 (referred to as: soluble AAVR). MBP was specifically used as an affinity tag for ease of purification.
To create AAVR fusion constructs, Ci-MPR-tail, LDLR-tail and PVR-tail, the Gibson assembly reaction was used to fuse amplified miniAAVR without its C-terminal to the C-terminal of the respective proteins, and insert it into the pLenti-CMV-Puro-DEST vector. Primers used for amplification and insertion included: miniAAVR without C-terminal and transmembrane domain for Ci-MPR-tail: 5′-GACTCTAGTCCAGTGTGGTG-3′ and 5′-CTTATTGTTTTCAGGTTGCACAAT-3′; MPR C-terminal and transmembrane: 5′-ATTGTGCAACCTGAAAACAATAAGGCTGTGGGAGCTGTGC-3′ and 5′-CGGCCGCCACTGTGC-3′; miniAAVR without C-terminal and transmembrane domain for LDLR-tail or PVR-tail: 5′-GACTCTAGTCCAGTGTGGTG-3′ and 5′-CTTATTGTTTTCAGGTTGCACAAT-3′; LDLR or PVR C-terminal and transmembrane: 5′-ATTGTGCAACCTGAAAACAATAAG-3′ and 5′-TAAATCCAGCACAGTGGCGGCCG-3′. Generation of stable cell lines. Lentiviral transduction was used to create stable cell lines expressing a selected gene of interest under a CMV promoter. Using Gibson assembly reaction, the respective genes of interest (see 'construction of plasmids' section) were inserted into the pLenti-CMV-Puro-DEST vector, and used as described previously 29 . Lentivirus was produced using HEK293 cells and used to transduce the respective cell lines overnight. Cells stably expressing the gene of interest were selected by treatment with 1-3 μg ml −1 puromycin over 2 days (InvivoGen). A lentivirus carrying the mCherry (RFP) gene was used as a control for AAVR complementation in AAVR KO cells. Flow cytometry. All flow cytometry was performed at the Stanford Shared FACS facility. To perform the haploid genetic screen, FACS was carried out on a FACS Aria flow cytometer (BD). To measure virus transgene expression (RFP/GFP) in all other experiments, cells were trypsinized 24 h after infection and a LSRII-UV flow cytometer (BD) was used to detect fluorescent cells. For cell surface staining, cells were trypsinized and washed using FACS buffer (PBS supplemented with 2% FCS, 1 mM EDTA and 0.1% sodium azide). They were subsequently incubated for 40 min at 4 °C with the respective primary antibodies at a 1:50 dilution (see ' Antibodies' section), washed, and incubated for a further 40 min at 4 °C with Alexa488-or Alexa594-conjugated secondary antibodies (1:500 dilution; if the primary was not conjugated) (Life Technologies). This was followed by a final wash and resuspension of cells in FACS buffer before reading fluorescence. All data presented are representative of at least two independent experiments. Data were analysed and assembled using FlowJo software (TreeStar Inc). Immunoblot analysis. Cell pellets of 2 × 10 6 cells were lysed with Laemmli SDS sample buffer containing 5% β-mercaptoethanol and boiled for 10 min at 96 °C. Lysates were separated by SDS-PAGE using the Mini-Protean system (Bio-Rad) on 4-15% polyacrylamide gradient gels (Bio-Rad). Proteins were transferred onto polyvinylidene fluoride membranes (Bio-Rad) using the Bio-Rad Transblot protein transfer system in a semi-wet preparation. Membranes were blocked by incubating with PBS containing 5% non-fat milk for 1 h at room temperature. Membranes were subsequently incubated overnight at 4 °C with primary antibodies at a dilution of 1:1000 (anti-KIAA0319L antibody) or 1:2,000 (anti-GAPDH antibody) in blocking buffer. Membranes were washed 3 times for 5 min using wash buffer (PBS with 0.1% Tween-20), and further incubated in horseradish peroxidase (HRP)conjugated secondary antibodies (anti-mouse and anti-rabbit 1:5,000 in blocking buffer) (GeneTex) for 1 h at room temperature. After another set of three washes, antibody-bound proteins were visualized on film using the West Pico and Extended Duration chemiluminescence peroxide solutions (Thermo Scientific). Immunofluorescence. Cells were seeded overnight at 40,000 cells per well onto LabTekII glass chamber slides (Thermo Scientific). They were washed once with PBS, and either treated or fixed immediately with 4% paraformaldehyde for 15 min. They were washed three times with PBS before being incubated for 1 h at room temperature with primary antibodies against the respective proteins at a dilution of 1:100 (anti-KIAA0319L and anti-TGN46) or 1:200 (anti-giantin) in immunofluorescence blocking buffer (PBS with 3% BSA, 1% saponin and 1% Triton X-100). Cells were then washed three times in PBS, and incubated for a further hour in DAPI stain (1:500) and fluorescently tagged secondary antibodies (Alexa488 anti-mouse and Alexa594 anti-rabbit; Life Technologies) at a dilution of 1:300. Cells were washed a final three times in PBS, and 5 μl of Vectashield (Vector Laboratories Inc) was applied to each slide chamber before a glass cover slip (VWR International) was placed over slide to mount samples. Cells were visualized directly with a Zeiss LSM 700 confocal microscope. ELISA. Purification of the soluble AAVR was achieved through amylose-based MBP affinity chromatography (GE Healthcare). ELISA plates (Corning Costar) were coated overnight at 4 °C with 50 μl AAV2 virus-like particles at 2.5 μg ml −1 in 100 mM NaHCO 3 (pH 9.6). Plates were then washed with TBST buffer (0.05% Tween-20 in TBS) and blocked with 3% BSA in TBST for 1 h at room temperature. Subsequent washing was followed by incubation with soluble AAVR or MBP control at the indicated concentrations for 2 h at room temperature. Anti-MBP-HRP (1:500, 1 h incubation at room temperature) was used to detect soluble AAVR and MBP controls, requiring no secondary antibody. Samples were developed with 1-Step Ultra TMB-ELISA substrate as per the manufacturer's instructions (Thermo Scientific) and optical density assayed by microplate reader (Molecular Devices SpectraMax M2 e ) at 450 nm. Curve fitting was performed in SigmaPlot v12.5 (Systat Software, Inc). All data presented are representative of at least three independent experiments. Surface plasmon resonance analysis of binding. Surface plasmon resonance analysis was carried out using a BIAcore X instrument (GE Healthcare) and a flow rate of 10 μl min −1 at 20 °C in HBS-P buffer (10 mM HEPES (pH 7.5), 150 nM NaCl and 0.005% surfactant P20). His-tagged soluble AAVR (His-tagged MBP fusion with AAVR PKD domains 1-5) at various concentrations was mixed with His-tagged MBP to a total concentration of 0.2 μM in 10 mM sodium acetate buffer (pH 4.0) and immobilized on a CM5 sensor chip by amide coupling. MBP at 0.2 μM was sufficient to block nonspecific binding to the dextran. For the analysis of binding affinity, all curves were measured in triplicate and were fitted with a Langmuir 1:1 binding model (BIAevaluation software, GE Healthcare). Antibody inhibition assay. Wild-type HeLa cells were seeded in 96-well plates at 10,000 cells per well overnight. Anti-AAVR antibody (ab105385) or IgG isotype control (both from Abcam) were incubated with cells (at concentrations ranging from 0.5 to 50 μg ml −1 in DMEM media) for 1 h at 4 °C. Cells were then infected with AAV2-luciferase at a MOI of 1,000 vg per cell, and left for 24 h at 37 °C. A luciferase assay kit (E1500, Promega) was used to detect bioluminescence, with measurements being taken on the Promega GloMax luminometer. Notably, the storage buffers of both antibodies did not contain preservatives such as azide that could interfere with the assay. All data presented are representative of two independent experiments. Competitive inhibition assay. HeLa cells were seeded in 96-well plates at 10,000 cells per well overnight. Purified soluble AAVR or MBP control was then introduced to the medium at the specified concentrations. Cells were transduced with AAV2-GFP at a MOI of 7,500 vg per cell and incubated for 24 h at 37 °C. This was followed by trypsinization and measuring transgene expression by flow cytometry. For immunofluorescence imaging, the concentration of soluble AAVR and MBP controls was 0.1 μM, and transduction was performed using 7,000 vg per cell. At 24 h post-transduction, cells were incubated with 1 μg ml −1 Hoechst stain (Thermo Scientific) in PBS for 10 min at 37 °C, before washing with PBS and subsequent fluorescent imaging (Nikon Eclipse Ti-E). All data presented are representative of two independent experiments. Tracking surface-bound AAVR using anti-AAVR antibodies. These experiments were performed similarly to Ci-MPR tracking assays, as described in ref. 31 . AAVR KO cells with or without overexpression of AAVR or ΔC-tail were incubated at 4 °C with anti-AAVR antibodies (approximately 25 μg ml −1 ) for 1 h. Cells were then washed three times with PBS and transferred to 37 °C for specific time points (2, 10, 30 and 60 min), at which time they were fixed with 4% paraformaldehyde for 15 min. Following fixation, immunofluorescence staining (as described earlier) was performed to visualize AAVR endocytosis. All data presented are representative of two independent experiments. Ethics statement and animal studies. All the experiments involving animals were conducted in strict accordance with the Institutional Animal Care and Use Committee of Stanford University. Mice were housed in a Stanford University vivarium, accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International. Mice were housed in irradiated disposable caging (Innovive Inc) with bi-weekly cage changes. Mice were provided with irradiated food and ultraviolet-irradiated acidified water. Health surveillance was performed via trimester testing of dirty bedding CD1 sentinels (Charles River Laboratories). Sentinels were consistently negative for mouse parvovirus, minute virus of mice, mouse hepatitis virus, rotavirus, mouse encephalomyelitis virus, Sendai virus, mouse adenovirus 1 and 2, ectromelia virus, lymphocytic choriomeningitis virus, pneumonia virus of mice, reovirus 3, Mycoplasma pulmonis, and endo-and ectoparasites. No statistical methods were used to predetermine sample size. In our animal study protocol, we state that the number of animals in each experimental group varies, and is based on similar previous study 32 . Randomization was not used to allocate animals to experimental groups and the investigators were not blinded to allocation during experiments and outcome assessment. AAV infection in mice. TALEN technology was used to create AAVR isogenic knockout FVB mice (purchased from Cyagen Biosciences). TALEN-targeted sequences were 5′-TGGGAGTCAAGCCAAGTC-3′ and 5′-GCCAGGATATTGTTGGCAGA-3′. Two founder males were mated to FVB/ NCrl (Charles River Laboratories) females. After three rounds of breeding, wildtype (Aavr +/+ ), heterozygous (Aavr +/− ) and homozygous AAVR KO (Aavr −/− ) mice were generated, determined by genotyping. All genotypes (wild-type, heterozygous Letter reSeArCH Extended Data Figure 3 | AAVR is a critical host factor for AAV2 infection. a, Effect of AAVR isogenic knockout (AAVR KO ) upon AAV2luciferase infection, evaluated in HAP1 and HeLa cell background from a MOI of 100 to 100,000 vg per cell. b, RT-qPCR to detect wild-type AAV2 infection in wild-type HeLa or AAVR KO cells. Cells were infected with wild-type AAV2 and adenovirus (helper virus required for AAV2 replication), and AAV2 Rep68 mRNA levels were measured to assess AAV2 infection. c, Immunoblot analysis evaluating AAVR expression in wildtype, AAVR KO and AAVR KO overexpressing AAVR (AAVR Comp.) cell lines of HAP1 and HeLa origin. GAPDH was immunoblotted as a control. AAVR (predicted 115 kilodaltons (kDa)) appears at 150 kDa owing to six glycosylation sites. d, AAV2-luciferase infection (MOI 20,000 vg per cell; measured after 24 h) in AAVR KO cells stably complemented with AAVR or control lentiviral vector, evaluated in several AAV2-susceptible human and mouse cell lines. e, Comparison of AAV2-RFP infection (MOI: 20,000 vg per cell; measured after 24 h) in wild-type, AAVR KO , MET KO and FGFR1 KO cells, evaluated in several AAV2-susceptible human cell lines. Data depict the mean and s.d. for triplicate infections.
